🇺🇸 FDA
Patent

US 11166937

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

granted A61KA61K31/352A61K31/366

Quick answer

US patent 11166937 (Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders) held by Amazentis SA expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Amazentis SA
Grant date
Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/352, A61K31/366, A61K31/7048, A61K36/185